Physician profile
Afton M Artz
NPI 1407348113
$1,896.44
in general payments reported to CMS, 2019-2025
20 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.44 · 2022: $235 · 2023: $342 · 2024: $754 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,487 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,487.22 |
| Education | $106.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $376.66 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $316.28 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $210.29 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $188.78 | 2022-2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $107.37 | 2021-2023 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.16 | 2022-2025 | Caplyta |
| Lundbeck LLC | $94.82 | 2022-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $89.56 | 2023-2025 | Quviviq, Quviviq |
| Vanda Pharmaceuticals INC. | $77.72 | 2022-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $62.00 | 2023-2025 | Rexulti |
| Almatica Pharma LLC | $52.83 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Abbvie INC. | $44.30 | 2022-2023 | |
| Noven Therapeutics, LLC | $31.88 | 2024 | Secuado, Xelstrym |
| Corium, LLC | $28.48 | 2023 | Azstarys |
| Sunovion Pharmaceuticals INC. | $25.34 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $22.08 | 2024 | Neurostar Tms Therapy System |
| Tris Pharma INC | $21.62 | 2024 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $19.27 | 2024 | Sunosi |
| Sage Therapeutics, LLC | $14.76 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afton Artz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.